A Phase 2 Study to Evaluate the Safety and Efficacy of YRA-1909 in Patients With Rheumatoid Arthritis

NCT03275025 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

116

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis

Interventions

DRUG: YRA-1909 low dose
DRUG: YRA-1909 mid dose
DRUG: YRA-1909 high dose
DRUG: Placebo

Sponsor

Yungjin Pharm. Co., Ltd.